Margaret G. Mcglynn - 31 Mar 2022 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
Director
Signature
/s/ Sabrina Yohai, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
31 Mar 2022
Net transactions value
-$1,311,346
Form type
4
Filing time
04 Apr 2022, 16:05:30 UTC
Previous filing
01 Feb 2022
Next filing
12 Apr 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Options Exercise $637,700 +5,000 +455% $127.54 6,099 31 Mar 2022 Direct
transaction VRTX Common Stock Sale $266,244 -1,019 -17% $261.28 5,080 31 Mar 2022 Direct F1, F2, F3
transaction VRTX Common Stock Sale $779,239 -2,970 -58% $262.37 2,110 31 Mar 2022 Direct F1, F3, F4
transaction VRTX Common Stock Sale $265,863 -1,011 -48% $262.97 1,099 31 Mar 2022 Direct F1, F3, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRTX Common Stock (right to buy) Options Exercise $637,700 -5,000 -33% $127.54 10,000 31 Mar 2022 Common Stock 5,000 $127.54 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Ms. McGlynn's company approved trading plan under Rule 10b5-1.
F2 Open market sales reported on this line occurred at a weighted average price of $261.28 (range $260.78 to $261.73).
F3 Ms. McGlynn undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4 Open market sales reported on this line occurred at a weighted average price of $262.37 (range $261.79 to $262.78).
F5 Open market sales reported on this line occurred at a weighted average price of $262.97 (range $262.80 to $263.34).
F6 Fully vested